Document is current
Any future updates will be listed below
-
Authors
Säemann, Marcus
Cejka, Daniel
Schmaldienst, Sabine
Rosenkranz, Alexander R.
Mayer, Gert
- License Information
-
More Information
Article History
Received: 6 April 2022
Accepted: 13 September 2022
First Online: 17 October 2022
Conflict of interest
: M. Säemann: advisory boards and speakers’ honoraria from AstraZeneca, Boehringer, Novo Nordisk, Novartis, and Otsuka. D. Cejka: advisory Boards honoraria from AstraZeneca and Boehringer Ingelheim; speaker’s honoraria from AstraZeneca; research grant from AstraZeneca. S. Schmaldienst: advisory Boards and speakers’ honoraria from AstraZeneca. A.R. Rosenkranz: personal fees from Astellas, Astra Zeneca, Baxter, Boehringer Ingelheim, GE, GSK, Novartis and Vifor. G. Mayer: advisory Boards and speakers’ honoraria from Astra Zeneca, Bayer, Boehringer Ingelheim, Novo Nordisk and Novartis.
